Comparative Pharmacology
Head-to-head clinical analysis: NORDETTE 28 versus NORETHIN 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORDETTE 28 versus NORETHIN 1 35E 28.
NORDETTE-28 vs NORETHIN 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
Combination estrogen-progestin oral contraceptive. Ethinyl estradiol suppresses FSH and LH, preventing ovulation. Norethindrone alters cervical mucus and endometrial lining, inhibiting sperm penetration and implantation.
One tablet orally once daily for 28 consecutive days.
One tablet orally once daily for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 35 mcg, followed by 7 inert tablets).
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Norethindrone: terminal elimination half-life approximately 8-11 hours. Ethinyl estradiol: terminal elimination half-life approximately 10-20 hours (mean ~13 hours). Clinical context: Steady-state achieved within 5 days; once-daily dosing maintains therapeutic levels.
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Norethindrone is excreted primarily in urine as glucuronide and sulfate conjugates, with about 50-60% excreted renally; approximately 20-30% is excreted in feces via biliary elimination. Ethinyl estradiol is excreted in urine (40-60%) and feces (20-40%) after enterohepatic recirculation.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive